New Rhenium Radiopharmaceuticals for the Selective Imaging and Therapy of Breast Cancer
Abstract
This report describes progress achieved during year-2 of a three year project, which seeks to develop new technology to produce rhenium radiopharmaceuticals for the diagnostic imaging and therapy of breast cancer. We have carried out rhenium labeling reactions using polymer-supported estradiol hydrazine precursors under highly dilute conditions, simulating radiolabeling conditions. The labeling reactions are successful using either the rhenium(V) oxo complex ReOCL3(PPh3)2 or perrhenate as the starting material. Labeling reactions are 50% complete after 2 hours at 40 degrees C. Two polymer supports have been investigated, carboxypolystyrene and the polystyrene-polyethyleneglycol conjugate Tentagel. The latter provided better yields of labeled product. The organoimidorhenium complexes I and II were stable in aqueous dimethylformamide solutions, and were not degraded by the presence of cysteine. Estrogen receptor binding affinities of the organoimidorhenium complexes I and II have been assayed and found to exhibit relative binding affinities of 4.47% and 3.39% respectively. The efficiency of the labeling chemistry, the complex stability in aqueous solvents, and the initial assessment of the receptor binding affinity of these complexes are all promising for this new class of potential rhenium radiopharmaceuticals.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 1999
- Accession Number
- ADA373946
Entities
People
- Jeffery B. Arterburn
Organizations
- New Mexico State University